american heart association glp 1 Obesity and GLP-1 RAs GLP-1 medications: What they are

P., Hallas, J

Therefore, they are nowadays recommended as first line therapy in patients with T2DM and atherosclerotic cardiovascular disease to reduce events, regardless of baseline or target HbA1c and concomitant glucose-lowering medication according to the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes [31]

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

Run small, controlled experiments, not broad guesses

17 A recent study found that MAFLD was present in 39% of patients with acute pancreatitis